CTOs on the Move

Advarra

www.advarra.com

 
Advarra advances the way clinical research is conducted: bringing life sciences companies, CROs, research sites, investigators, and academia together at the intersection of safety, technology, and collaboration. With trusted IRB and IBC review solutions, innovative technologies, experienced consultants, and deep-seated connections across the industry, Advarra provides integrated solutions that safeguard trial participants, empower clinical sites, ensure compliance, and optimize research performance. Advarra is advancing clinical trials to make them safer, smarter, and faster.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.advarra.com
  • 6100 Merriweather Drive Suite 600
    Columbia, MD USA 21044
  • Phone: 410.884.2900

Executives

Name Title Contact Details
Jeff Sidell
Chief Technology Officer Profile
Eric Whitford
IT Director Profile
Nitin Uplekar
Chief Information Officer Profile
Jonathan Shough
President of Technology Solutions Profile

Jobs

Similar Companies

Precision Life Sciences

RESULTS ARE IN OUR DNA Fostering partnerships within the Life Science industry to enable innovation and positive outcomes. CLIENTS JOB SEEKERS Company We Are Precision Life Sciences Precision Life Sciences, a WBE (Woman-Owned Business Enterprise), was ...

Kleo

Kleo Pharmaceuticals is advancing the field of immunotherapy by developing small molecules that emulate biologics.

Imperative Care

Were reimagining how technology can solve #stroke`s unmet needs, enabling providers with the ability to raise the standard of care for patients.

CapsCanada

Were one of the world’s leading providers of high quality, empty, hard capsules serving global pharmaceutical and dietary supplement markets.

XTuit

XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response. The Company’s proprietary drug development pipeline and integrated, sophisticated clinical biomarker platform will be used for accelerated clinical development across selected cancers and fibrotic disorders. XTuit’s compounds act through pleiotropic mechanisms to inhibit extracellular matrix synthesis and stabilization, and to silence activated stromal cells, including cancer-associated fibroblasts and stellate cells. As a result, XTuit compounds alleviate hypoxia and enable enhanced drug uptake through solid stress reduction. Moreover, the drugs have been shown to down-regulate stroma-induced tumor and inflammation signaling pathways to overcome treatment resistance. XTuit’s first two lead series are being developed for early clinical proof-of-concept in liver diseases and cancer.